Last reviewed · How we verify
INSULIN, NEUTRAL
At a glance
| Generic name | INSULIN, NEUTRAL |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 2007 |
Approved indications
Common side effects
Key clinical trials
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- Effect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes (NA)
- Protocolized Reduction of Non-resuscitation Fluids Versus Usual Care in Septic Shock Patients (NA)
- Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt (PHASE2)
- A Comparison of Neuromuscular Recruitment in Trained and Untrained Adults
- Effect of Intraperitoneal Insulin Administration After Laparoscopy in Insulin-Resistant Patients on Prevention of Postoperative Adhesion Recurrence: A Randomized Controlled Trial (NA)
- RCT Glargine vs NPH for Treatment of DM in Pregnancy (PHASE3)
- Protocolized Reduction of Non-resuscitation Fluids vs Usual Care in Septic Shock Feasibility Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INSULIN, NEUTRAL CI brief — competitive landscape report
- INSULIN, NEUTRAL updates RSS · CI watch RSS